2Sabino De Placido,Chiara Carlomagno,Michelino De Laurentiis,Angelo Raffaele Bianco. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients[J] 1998,Breast Cancer Research and Treatment(1-3):55～64
3Dr. Steven T. Brower MD,Sharmila Ahmed BA,Paul I. Tartter MD,Ira Bleiweiss MD,J. B. Amberson MD. Prognostic variables in invasive breast cancer: Contribution of comedo versus noncomedo in situ component[J] 1995,Annals of Surgical Oncology(5):440～444
2Baselga J, Tripathy D, Mendelsohn J, et al, Phase II study of weekly intravenous recombiTmnt humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. JClin Oncol, 1996, 14: 737-744.
3Vogel CL, Cobleigh MA, Tripalhy D, et al. First-line herceptin monolherapy in metastatic breast cancer. Oncology 2001,61 ( Suppl2).37-42.
4Fomier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin-Oncol,2000, 27: 38-45.
5Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1998, 58: 2825-2831.
